Sickle Cell Disease Drug Market
Global Sickle Cell Disease Drug Market Size, Share &Trends Report By Treatment (Blood Transfusion, Bone Marrow Transplant, and Pharmacotherapy) and by End User (Hospitals, Speciality Clinics, and others) Forecast (2022-2028)
The global sickle cell disease drug is anticipated to hold a considerable CAGR during the forecast period (2022-2028). Sickle cell disease refers to a group of disorders that cause red blood cells to become misshapen and break down. The rise in the prevalence of sickle cell diseases is expected to accelerate the market during the forecast period. For instance, according to the Center for Disease Control and Prevention (CDC) in 2020, sickle cell disease is commonly found among those whose ancestors came from sub-Saharan Africa. Further, according to the data published by CDC in 2020, around 0.1 million Americans are affected by sickle cell disease. Moreover, 1 out every 365 African –American births are affected by sickle cell disease, and about 1 in 13 African –American infants are born with sickle cell trait (SCT). Thus, owing to the rising prevalence of sickle cell disease, the global sickle cell disease drug is anticipated to grow at a significant rate during the forecast period.
Impact of COVID-19 Pandemic on global Sickle Cell Disease Drug Market
The COVID-19 pandemic has resulted in a decline in the growth of the sickle cell disease drug market. The COVID-19 has created a significant burden on the healthcare facilities owing to the rise in the prevalence of COVID-19 cases. Hence, many hospitals and government organizations have postponed non-elective surgeries to allocate resources to manage COVID-19 patients. Also, the prevalence of lockdowns and restrictions has disrupted the supply chain further leading to delayed business deals. Moreover, COVID-19 pandemic has resulted in a decline in the number of donors, owing to the unwillingness of the people to visit the hospital facilities due to the fear of getting infected.
Segmental Outlook
The global sickle cell disease drug market is segmented based on treatment and end-user. Based on treatment, the market is sub-segmented into Blood transfusion, bone marrow transplantation, and pharmacotherapy. Based on the end-user, the market is further sub-segmented into specialty clinics, hospitals, and others. Among these, the hospital segment is anticipated to hold a considerable share in the market during the forecast period owing to the rise in the number of emergency room visits.?
Global Sickle Cell Disease Drug by Treatment,2021 (%)
The Blood Transfusion Segment is Anticipated to Hold a Prominent Share in the Global Sickle Cell Disease Drug Market
According to the data published by the American Society of Hematology, in 2020, stroke, silent cerebral infracts, and cognitive morbidity are some of the major complications of sickle cell disease in children and adults. Further, approximately 11% of sickle cell disease patients are affected by strokes prior to age 20. Thus, blood transfusion is an effective method of treatment to prevent episodes of stroke among sickle cell disease patients. As a result, the blood transfusion segment is anticipated to hold a prominent share in the market, further boosting the growth of the global sickle cell disease drug market during the forecast period.
Regional Outlook
The global sickle cell disease drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these North, America segment is anticipated to hold a considerable share in the market owing to government collaborations to support the treatment for sickle cell disease.?
Global Sickle Cell Disease Drug Market, by Region 2022-2028
Africa, Middle East, Latin America, and Mediterranean regions are Estimated to Hold Major Share in Global Sickle Cell Disease Drug Market
The Middle East, Latin America, and Mediterranean regions are Estimated to Hold Major Share in the market. For, instance, in June 2020 Novartis AG expanded the Africa Sickle Cell Disease program to East Africa with two MoU, ministries of Health of Uganda and Ministries of Health of Tanzania to provide care to patients in sub-Saharan Africa. This program is anticipated to reach 10 countries by the end of 2022. The rising prevalence of sickle cell disease among adults and children is another major factor in driving the growth of the sickle cell disease drug market in the region. For instance, according to the data published by National Center for Biotechnology Information, in April 2020, it was estimated that 50 to 90% of SCA children died before age 5 years. Thus, the prevalence of sickle cell disease is anticipated to drive the global sickle cell disease drug market over the forecast period.
Market players Outlook
The major companies serving the global sickle cell disease drug market are Novartis AG, Global Blood Therapeutics Inc., Medunik USA Inc., Bristol-Myers Squibb Co, Emmaus Medical Inc., and more among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2019, Global Blood Therapeutics Inc. received the US Food and Drug Administration (FDA) approval for Oxbryta. Oxbryta is a prescription medicine used to treat sickle cell diseases in adults and children 4 years of age and older.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global sickle cell disease drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Sickle Cell Disease Drug Market
- Recovery Scenario of The Global Sickle Cell Disease Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Bristol-Myers Squibb Co.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Emmaus Medical Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Global Blood Therapeutics Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Medunik USA Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Novartis AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Sickle Cell Disease Drug Market by Treatment
4.1.1. Blood Transfusion
4.1.2. Bone Marrow Transplantation
4.1.3. Pharmacotherapy
4.2. Global Sickle Cell Disease Drug Market by End-user
4.2.1. Specialty Clinics
4.2.2. Hospitals
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Alnylam Pharmaceuticals, Inc.
6.2. Arena Pharmaceuticals, Inc.
6.3. AstraZeneca Plc.
6.4. Acceleron Pharma, Inc.
6.5. Bluebird bio, Inc.
6.6. Baxter International, Inc.
6.7. Daiichi Sankyo Co.
6.8. Dr. Reddy’s Laboratories, Ltd.
6.9. Eli Lilly &Co.
6.10. Johnson & Johnson Services, Inc.
6.11. SANOFI
6.12. Sangamo Therapeutics, Inc.
6.13. Novartis AG
6.14. Takeda Pharmaceutical Co., Ltd.
1. GLOBAL SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
2. GLOBAL BLOOD TRANSFUSION SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL BONE MARROW TRANSPLANTATION IN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL PHARMACOTHERAPY IN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
6. GLOBAL SPECIALTY CLINICS IN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL HOSPITALS IN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
9. NORTH AMERICAN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
11. NORTH AMERICAN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
12. EUROPEAN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. EUROPEAN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
14. EUROPEAN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
15. ASIA-PACIFIC END STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT 2021-2028 ($ MILLION)
17. ASIA-PACIFIC END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
18. REST OF THE WORLD SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. REST OF THE WORLD SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
20. REST OF THE WORLD SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL SICKLE CELL DISEASE DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL SICKLE CELL DISEASE DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL SICKLE CELL DISEASE DRUG MARKET, 2021-2028 (%)
4. GLOBAL SICKLE CELL DISEASE DRUG MARKET SHARE BY TREATMENT, 2021VS 2028 (%)
5. GLOBAL BLOOD TRANSFUSION IN SICKLE CELL DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
6. GLOBAL BONE MARROW TRANSPLANTATION IN SICKLE CELL DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
7. GLOBAL PHARMACOTHERAPY IN SICKLE CELL DISEASE DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL SICKLE CELL DISEASE DRUG MARKET SHARE BY END-USER, 2021VS 2028 (%)
9. GLOBAL CLINICS IN SICKLE CELL DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
10. GLOBAL HOSPITALS IN SICKLE CELL DISEASE DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
11. US SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
12. CANADA SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
13. UK SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
14. FRANCE SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
15. GERMANY SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. ITALY SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. SPAIN SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. REST OF EUROPE SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. INDIA SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. CHINA SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. JAPAN SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. SOUTH KOREA SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF ASIA-PACIFIC SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF THE WORLD SICKLE CELL DISEASE DRUG MARKET SIZE, 2021-2028 ($ MILLION)
